[¹⁸ F]Fluoroethoxybenzovesamicol in Parkinson's disease patients: Quantification of a novel cholinergic positron emission tomography tracer

Mov Disord. 2019 Jun;34(6):924-926. doi: 10.1002/mds.27698. Epub 2019 Apr 12.

Authors

Sygrid van der Zee¹, David Vállez García², Philip H Elsinga², Antoon T M Willemsen², Hendrikus H Boersma^{2

3}, Marleen J J Gerritsen¹, Jacoba M Spikman¹, Teus van Laar¹

Affiliations

¹ Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
² Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
³ Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, the Netherlands.

PMID: 30977934
DOI: 10.1002/mds.27698

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Brain / diagnostic imaging*
Humans
Parkinson Disease / diagnostic imaging*
Piperidines*
Positron-Emission Tomography / methods

Substances

Piperidines
fluoroethoxy-benzovesamicol